Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / T-MAXIMUM Pharmaceutical Inc

Clinicaltrial registered27 Oct 2026

T-MAXIMUM Pharmaceutical Inc

27 Oct 2026: Trial registered · The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid Tumors. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
27 Oct 2026
Title
The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid Tumors
Conditions
Brain Metastases From Solid Tumors
Phase
Phase 2
Study Type
Interventional
Status
Not Yet Recruiting
Countries
United States, Taiwan
Country
United States
Reference
NCT07897799
Location
United States, Taiwan
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at T-MAXIMUM Pharmaceutical Inc

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from United States

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.